Intensified Rituximab Induction Followed By Rituximab Maintenance For Low Grade B Cell Lymphoma: A Multicenter, Phase II Study

被引：0
|
作者：
Yamada, Kyouhei
Sawamura, Mario
Shimomura, Takeshi
Takeuchi, Makoto
Hanada, Shuichi
Komeno, Takuya
Hidaka, Michihiro
Yano, Takahiro
Kitano, Kiyoshi
Yoshida, Isao
Inoue, Nobumasa
Horibe, Keizo
Tomoyuki, Watanabe
Sunami, Kazutaka
Nagai, Hirokazu
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1797.1797
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1797
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Induction with fludarabine, cyclophosphamide and rituximab followed by maintenance with rituximab: Results of a prospective study in 75 patients (LNHF-03).
    Tomas, Jose F.
    Montalban, Carlos
    Martinez-Lopez, Joaquin
    Paz, Jose
    Canales, Miguel
    Diaz-Mediavilla, Joaquin
    Godoy, Pedro Sanchez
    de Sevilla, Alberto Fdez
    Penalver, Javier
    Caballero, MDolores
    Prieto, Elena
    Salar, Jose
    de Ona, Raquel
    De la Serna, Javier
    BLOOD, 2006, 108 (11) : 782A - 782A
  • [42] Results of a phase II multicenter trial of pentostatin and rituximab in patients with low-grade B-cell non-Hodgkin's lymphoma: An effective and minimally toxic regimen
    Drapkin, R
    Di Bella, NJ
    Faragher, DC
    Harden, E
    Matei, C
    Hyman, W
    Mirabel, M
    Boehm, KA
    Asmar, L
    CLINICAL LYMPHOMA, 2003, 4 (03): : 169 - 175
  • [43] Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study
    Craig, Michael
    Hanna, Wahid T.
    Cabanillas, Fernando
    Chen, Chien-Shing
    Parasuraman, Sudha
    Neuwirth, Rachel
    O'Connor, Owen A.
    BLOOD, 2010, 116 (21) : 1153 - 1154
  • [44] Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.
    Laurent, Guy
    de Micheaux, Sylvie Lafaye
    Solal-Celigny, Philippe
    Soubeyran, Pierre
    Delwail, Vincent
    Ghesquieres, Herve
    Thieblemont, Catherine
    Jourdan, Eric
    Beautier, Lucile
    Audibert, Fabien
    Squiban, Patrick
    Sicard, Helene
    Rossi, Jean-Francois
    BLOOD, 2009, 114 (22) : 658 - 659
  • [45] Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden
    Igarashi, Tadahiko
    Ogura, Michinori
    Itoh, Kuniaki
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Kuroda, Yoshiaki
    Yamamoto, Kazuhito
    Uike, Naokuni
    Tomita, Akihiro
    Nagai, Hirokazu
    Kurosawa, Mitsutoshi
    Mori, Shigeo
    Nawano, Shigeru
    Terauchi, Takashi
    Ohashi, Yasuo
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (06) : 700 - 708
  • [46] Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden
    Tadahiko Igarashi
    Michinori Ogura
    Kuniaki Itoh
    Masafumi Taniwaki
    Kiyoshi Ando
    Yoshiaki Kuroda
    Kazuhito Yamamoto
    Naokuni Uike
    Akihiro Tomita
    Hirokazu Nagai
    Mitsutoshi Kurosawa
    Shigeo Mori
    Shigeru Nawano
    Takashi Terauchi
    Yasuo Ohashi
    Kensei Tobinai
    International Journal of Hematology, 2016, 104 : 700 - 708
  • [47] Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma
    Cowan, Andrew J.
    Stevenson, Phillip A.
    Gooley, Ted A.
    Frayo, Shani L.
    Oliveira, George R.
    Smith, Stephen D.
    Green, Damian J.
    Roden, Jennifer E.
    Pagel, John M.
    Wood, Brent L.
    Press, Oliver W.
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (04) : 583 - 590
  • [48] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Matsumoto, Yosuke
    Kobayashi, Tsutomu
    Shimura, Yuji
    Kawata, Eri
    Nagoshi, Hisao
    Ohshiro, Muneo
    Sugitani, Mio
    Shimura, Kazuho
    Iwai, Toshiki
    Fuchida, Shin-ichi
    Yoshida, Mihoko
    Kiyota, Miki
    Mizutani, Shinsuke
    Chinen, Yoshiaki
    Takimoto-Shimomura, Tomoko
    Nakao, Mitsushige
    Kaneko, Hiroto
    Uchiyama, Hitoji
    Uoshima, Nobuhiko
    Nishigaki, Hikari
    Kobayashi, Yutaka
    Horiike, Shigeo
    Shimazaki, Chihiro
    Taniwaki, Masafumi
    Kuroda, Junya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (01) : 77 - 85
  • [49] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Yosuke Matsumoto
    Tsutomu Kobayashi
    Yuji Shimura
    Eri Kawata
    Hisao Nagoshi
    Muneo Ohshiro
    Mio Sugitani
    Kazuho Shimura
    Toshiki Iwai
    Shin-ichi Fuchida
    Mihoko Yoshida
    Miki Kiyota
    Shinsuke Mizutani
    Yoshiaki Chinen
    Tomoko Takimoto-Shimomura
    Mitsushige Nakao
    Hiroto Kaneko
    Hitoji Uchiyama
    Nobuhiko Uoshima
    Hikari Nishigaki
    Yutaka Kobayashi
    Shigeo Horiike
    Chihiro Shimazaki
    Masafumi Taniwaki
    Junya Kuroda
    International Journal of Hematology, 2019, 110 : 77 - 85
  • [50] A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
    Boccomini, Carola
    Ladetto, Marco
    Rigacci, Luigi
    Puccini, Benedetta
    Rattotti, Sara
    Volpetti, Stefano
    Ferrero, Simone
    Chiarenza, Annalisa
    Freilone, Roberto
    Novo, Mattia
    Corradini, Paolo
    Nassi, Luca
    Rusconi, Chiara
    Stelitano, Caterina
    Bolis, Silvia
    Marina Liberati, Anna
    Tucci, Alessandra
    Baldini, Luca
    Balzarotti, Monica
    Evangelista, Andrea
    Ciccone, Giovannino
    Vitolo, Umberto
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (02) : 280 - 289
12345